India's Advanced Enzymes Technologies soars on post-COVID-19 trial data

Advanced Enzyme Technologies

13/09/2021 07:32

** Enzyme maker's shares  ADEN.NS  jump as much as 14.3% to
418.80 rupees - on track for best day in nearly a year
    ** ADEN's enzyme and probiotic supplements showed a 91%
resolution of post-COVID-19 fatigue symptoms in the test arm of
a 200-patient trial  urn:newsml:reuters.com:*:nFWN2QE0BJ
    ** Muscle fatigue and cognitive disturbances persist in
patients recovering from acute COVID-19 and recent trials 
suggest that nutraceuticals aid in recovery - ADEN
    ** ADEN stock touches highest level in more than a month
    ** Including session's gains, stock up more than 25% this
year

 (Reporting by Shivani Singh in Bengaluru)
 ((ShivaniSingh1@thomsonreuters.com; +91 89 6969 2349))